This editorial describes the science behind the treatment of children with hemophilia A with efanesoctocog alfa, a bioengineered recombinant factor VIII protein.
The New England Journal of Medicine: Search Results in Pediatrics
Science behind the Study: Bioengineered Factor VIII — More Innovation for Hemophilia A
